Y-mAbs Therapeutics

Company snapshot

Y-mAbs is a commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. We have a broad and advanced product pipeline, including pivotal-stage product candidates against a range of targets. Our mission is to become the world leader in developing better and safer antibody-based oncolo

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Y-mAbs Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Y-mAbs Therapeutics.

1. Jun 8, 2026 Clinical update

   201 — Phase 2

View all clinical trial activity →

• What is Y-mAbs Therapeutics?

  Y-Mabs Therapeutics A/S is a pharma organization headquartered in EU. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (1).

• Is Y-mAbs Therapeutics publicly traded?

  Y-mAbs Therapeutics appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Y-mAbs Therapeutics develop or market?

  We link 5 drug profile(s) where Y-mAbs Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/y-mabs-therapeutics-a-s#company-drugs.

• What are the latest developments for Y-mAbs Therapeutics?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Y-mAbs Therapeutics focus on?

  No specific therapeutic focus areas are currently identified for Y-mAbs Therapeutics in our database.